Baricitinib is the first JAK inhibitor (selective and reversible inhibitor of JAK 1 and JAK2) that has been approved in Europe by EMA on 17 September 2020 for the treatment of moderate to severe AD [24]. This evidence concerns the gene JAK2 and Alzheimer disease.